Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase;Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC) 2017. Tratamiento farmacológico en fase estable

Archivos de Bronconeumologia

Volumn 53, Issue 6, 2017, Pages 324-335

  Miravitlles, Marc ^a,b   Soler Cataluña, Juan José ^c   Calle, Myriam ^d   Molina, Jesús ^e   Almagro, Pere ^f   Quintano, José Antonio ^g   Trigueros, Juan Antonio ^h   Cosío, Borja G ^b,i   Casanova, Ciro ^j   Antonio Riesco, Juan ^k   Simonet, Pere ^l   Rigau, David ^m   Soriano, Joan B ⁿ   Ancochea, Julio ⁿ  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL ARNAU DE VILANOVA   (Spain)

^d SCHOOL OF MEDICINE   (Spain)

^e Centro de Salud Francia   (Spain)

^f HOSPITAL MÚTUA DE TERRASSA   (Spain)

^g Centro de Salud Lucena I   (Spain)

^h Centro de Salud Menasalbas   (Spain)

ⁱ HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^j HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^k HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^l Research Institute University Primary Care IDIAP Jordi Gol   (Spain)

^m Centro Cochrane Iberoamericano   (Spain)

ⁿ HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

more..

Author keywords

Chronic obstructive pulmonary disease; Guidelines; Phenotypes; Treatment

Indexed keywords

BRONCHODILATING AGENT; ACLIDINIUM BROMIDE; FORMOTEROL; GLYCOPYRRONIUM; INDACATEROL; IPRATROPIUM BROMIDE; OLODATEROL; ROFLUMILAST; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; UMECLIDINIUM; VILANTEROL; ALPHA 1 ANTITRYPSIN; ANTIINFECTIVE AGENT; ANTIOXIDANT; CORTICOSTEROID; EXPECTORANT AGENT; PHOSPHODIESTERASE INHIBITOR;

ARTICLE; ASTHMA; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; HIGH RISK PATIENT; HUMAN; LOW RISK PATIENT; LUNG EMPHYSEMA; LUNG FUNCTION; PRACTICE GUIDELINE; RISK ASSESSMENT; SPAIN; EMPHYSEMA; EVIDENCE BASED MEDICINE; MEDICAL HISTORY; MONOTHERAPY; PHENOTYPE; TREATMENT INDICATION; COMPLICATION; DISEASE MANAGEMENT; MEDICAL SOCIETY; ORGANIZATION AND MANAGEMENT; OXYGEN THERAPY; PULMONOLOGY; RESPIRATORY TRACT EXAMINATION; STANDARDS;

ADRENAL CORTEX HORMONES; ALPHA 1-ANTITRYPSIN; ANTI-BACTERIAL AGENTS; ANTIOXIDANTS; BRONCHITIS; BRONCHODILATOR AGENTS; DIAGNOSTIC TECHNIQUES, RESPIRATORY SYSTEM; DISEASE MANAGEMENT; EXPECTORANTS; OXYGEN INHALATION THERAPY; PHENOTYPE; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; PULMONARY MEDICINE; RISK ASSESSMENT; SOCIETIES, MEDICAL; SPAIN;

EID: 85018956123     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbres.2017.03.018     Document Type: Article

References (98)

1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545-602.
2. Miravitlles, M., Soler-Cataluña, J.J., Calle, M., Molina, J., Almagro, P., Quintano, J.A., et al., Spanish COPD guidelines (GesEPOC). Pharmacological treatment of stable COPD. Arch Bronconeumol 48 (2012), 247–257.
3. Koblizek, V., Chlumsky, J., Zindr, V., Neumannova, K., Zatloukal, J., Zak, J., et al., Czech Pneumological and Phthisiological Society. Chronic obstructive pulmonary disease: Official diagnosis and treatment guidelines biomed of the Czech Pneumological and Phthisiological society: A novel phenotypic approach to COPD with patient oriented care. Pap Med Fac Univ Palacky Olomouc Czech Repub 157 (2013), 189–201.
4. Kankaanranta, H., Harju, T., Kilpeläinen, M., Mazur, W., Lehto, J.T., Katajisto, M., et al. Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: The Finnish guidelines. Guidelines of the Finnish Medical Society Duodecim and the Finnish Respiratory Society. Basic Clin Pharmacol Toxicol, 2013, 10.1111/bcpt.12366.
5. Calle, M., Alcázar, B., Soriano, J.B., Soler-Cataluña, J.J., Rodríguez, J.M., Fuentes, M., et al. Clinical audit of COPD in outpatient respiratory clinics in Spain: The EPOCONSUL study. Int J Chron Obstruct Pulm Dis 12 (2017), 417–426.
6. Alonso-Coello, P., Rigau, D., Juliana Sanabria, A., Plaza, V., Miravitlles, M., Martínez, L., Calidad y fuerza: el sistema GRADE para la formulación de recomendaciones en las guías de práctica clínica. Arch Bronconeumol 49 (2013), 261–267.
7. Grupo de Trabajo de GesEPOC. Guía de Práctica Clínica para el Diagnóstico y Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) - Guía Española de la EPOC (GesEPOC). Versión 2017. Arch Bronconeumol 53:ext 1 (2017), 4–64.
8. Hansen, J.E., Sun, X.G., Wasserman, K., Spirometric criteria for airway obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not < 70%. Chest 131 (2007), 349–355.
9. Vogelmeier, C.F., Criner, G.J., Martínez, F.J., Anzueto, A., Barnes, P.J., Bourbeau, J., et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Arch Bronconeumol. 53 (2017), 128–149.
10. Soriano, J.B., Lamprecht, B., Ramírez, A.S., Martinez-Camblor, P., Kaiser, B., Alfageme, I., et al. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: A pooled analysis of individual patient data. Lancet Respir Med 3 (2015), 443–450.
11. Celli, B.R., Cote, C.G., Marín, J.M., Casanova, C., Montes de Oca, M., Mendez, R.A., et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350 (2004), 1005–1012.
12. Soler-Cataluña, J.J., Martínez-García, M.A., Sánchez, L., Perpiña, M., Román, P., Severe exacerbations and BODE index: Two independent risk factors for death in male COPD patients. Respir Med 103 (2009), 692–699.
13. Cosio, B.G., Soriano, J.B., López-Campos, J.L., Calle, M., Soler, J.J., de-Torres, J.P., et al. CHAIN study. Distribution and outcomes of a phenotype-based approach to guide COPD management: Results from the CHAIN cohort. PLoS One, 11, 2016, e0160770.
14. Miravitlles, M., Alvarez-Gutierrez, F., Calle, M., Casanova, C., Cosío, B.G., López-Viña, A., et al. Algorithm for identification of ACO: Consensus between the Spanish COPD (GesEPOC) and asthma (GEMA) guidelines. Eur Respir J., 49, 2017, 1700068.
15. Hurst, J.R., Vestbo, J., Anzueto, A., Locantore, N., Müllerova, H., Tal-Singer, R., et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363 (2010), 1128–1138.
16. Soler Cataluña, J.J., Martínez García, M.A., Catalán Serra, P., The frequent exacerbator. A new phenotype in COPD?. Hot Topics Respir Med 6 (2011), 7–12.
17. Han, M.K., Kazerooni, E.A., Lynch, D.A., Liu, L.X., Murray, S., Curtis, J.L., et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: Associated radiologic phenotypes. Radiology 261 (2011), 274–282.
18. Martínez-García, F., Soler-Cataluña, J.J., Donat, Y., Catalán, P., Agramunt, M., Ballestin, V., et al. Factors associated with bronchiectasis in chronic obstructive pulmonary disease patients. Chest 140 (2011), 1130–1137.
19. Miravitlles, M., Marin, A., Monsó, E., Vilà, S., de la Roza, C., Hervás, R., et al. Colour of sputum is a marker of bacterial colonization in COPD. Respir Res, 11, 2010, 58.
20. Marin, A., Monsó, E., Garcia-Nuñez, M., Sauleda, J., Noguera, A., Pons, J., et al. Variability and effects of bronchial colonisation in patients with moderate COPD. Eur Respir J 35 (2010), 295–302.
21. Jiménez Ruiz, C.A., Riesco Miranda, J.A., Altet Gómez, N., Lorza Blasco, J.J., Signes-Costa Miñana, J., Solano Reina, S., et al. Tratamiento del tabaquismo en fumadores con enfermedad pulmonar obstructiva crónica. Arch Bronconeumol 49 (2013), 354–363.
22. Barreiro, E., Bustamante, V., Cejudo, P., Gáldiz, J.B., Gea, J., de Lucas, P., et al. SEPAR. Guidelines for the evaluation and treatment of muscle dysfunction in patients with chronic obstructive pulmonary disease. Arch Bronconeumol 51 (2015), 384–395.
23. Sestini, P., Renzoni, E., Robinson, S., Poole, P., Ram, F.S., Short-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2002, CD001495.
24. Boyd, G., Morice, A.H., Pounsford, J.C., Siebert, M., Peslis, N., Crawford, C., An evaluation of salmeterol in the treatment of the chronic obstructive pulmonary disease (COPD). Eur Respir J 10 (1997), 815–821.
25. Aalbers, R., Ayres, J., Backer, V., Decramer, M., Lier, P.A., Magyar, P., et al. Formoterol in patients with chronic obstructive pulmonary disease: A randomized, controlled, 3-month trial. Eur Respir J 19 (2002), 936–943.
26. Stockley, R.A., Whitehead, P.J., Williams, M.K., Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: Results of a meta-analysis. Respir Res, 7, 2006, 147.
27. Tashkin, D.P., Cooper, C.B., The role of long-acting bronchodilators in the management of stable COPD. Chest 125 (2004), 249–259.
28. Beier, J., Beeh, K.M., Long-acting β-adrenoceptor agonists in the management of COPD: Focus on indacaterol. Int J Chron Obstruct Pulmon Dis 6 (2011), 237–243.
29. Brusasco, V., Hodder, R., Miravitlles, M., Korducki, L., Towse, L., Kesten, S., Health outcomes following six months treatment with once daily tiotropium compared to twice daily salmeterol in patients with COPD. Thorax 58 (2003), 399–404.
30. Puhan, M.A., Bachmann, L.M., Kleijnen, J., Ter Riet, G., Kessels, A.G., Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: A network meta-analysis. BMC Med, 7, 2009, 2.
31. Vogelmeier, C., Hederer, B., Glaab, T., Schmidt, H., Rutten van Molkën, M.P.M.H., Beeh, K.M., et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364 (2011), 1093–1103.
32. Decramer, M.L., Chapman, K.R., Dahl, R., Frith, P., Devouassoux, G., Fritscher, C., et al., INVIGORATE investigators. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): A randomised, blinded, parallel-group study. Lancet Respir Med 1 (2013), 524–533.
33. Price, D., Østrem, A., Thomas, M., Welte, T., Dual bronchodilation in COPD: Lung function and patient-reported outcomes-a review. Int J Chron Obstruct Pulmon Dis 12 (2016), 141–168.
34. Calzetta, L., Rogliani, P., Matera, M.G., Cazzola, M., A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest 149 (2016), 1181–1196.
35. Schlueter, M., Gonzalez-Rojas, N., Baldwin, M., Groenke, L., Voss, F., Reason, T., Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: A systematic review and network meta-analysis. Ther Adv Respir Dis 10 (2016), 89–104.
36. Miravitlles, M., D'Urzo, A., Singh, D., Koblizek, V., Pharmacological strategies to reduce exacerbation risk in COPD: A narrative review. Respir Res, 17, 2016, 112.
37. Oba, Y., Sarva, S.T., Dias, S., Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: A network meta-analysis. Thorax 71 (2016), 15–25.
38. Ram, F.S., Jardin, J.R., Atallah, A., Castro, A.A., Mazzini, R., Goldstein, R., et al. Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis. Respir Med 99 (2005), 135–144.
39. Barrecheguren, M., Esquinas, C., Miravitlles, M., The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): Opportunities and challenges. Curr Opin Pulm Med 21 (2015), 74–79.
40. Bafadhel, M., McKenna, S., Terry, S., Mistry, V., Reid, C., Haldar, P., et al. Acute exacerbations of chronic obstructive pulmonary disease: Identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 184 (2011), 662–671.
41. Siva, R., Green, R.H., Brightling, C.E., Shelley, M., Hargadon, B., McKenna, S., et al. Eosinophilic airway inflammation and exacerbations of COPD: A randomised controlled trial. Eur Respir J 29 (2007), 906–913.
42. Pavord, I.D., Lettis, S., Locantore, N., Pascoe, S., Jones, P.W., Wedzicha, J.A., et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax 71 (2016), 118–125.
43. Welte, T., Miravitlles, M., Hernandez, P., Eriksson, G., Peterson, S., Polanowski, T., et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 180 (2009), 741–750.
44. Peters, S.P., Kunselman, S.J., Nikolina Icitovic, M.A., Moore, W.C., Pascual, R., Ameredes, B.T., et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 363 (2010), 1715–1726.
45. Wedzicha, J.A., Decramer, M., Ficker, J.H., Niewoehner, D.E., Sandström, T., Taylor, A.F., et al. Analysis of chronic obstructive pulmonar disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): A randomised, double-blind, parallel-group study. Lancet Respir Med 1 (2013), 199–209.
46. Wedzicha, J.A., Banerji, D., Chapman, K.R., Vestbo, J., Roche, N., Ayers, R.T., et al., FLAME Investigators. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 374 (2016), 2222–2234.
47. Calverley, P.M., Anderson, J.A., Celli, B., Ferguson, G.T., Jenkins, C., Jones, P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007), 775–789.
48. Nannini, L.J., Cates, C.J., Lasserson, T.J., Poole, P., Combined corticosteroid and long-acting beta-agonistin one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2007, CD006829.
49. Pascoe, S., Locantore, N., Dransfield, M.T., Barnes, N.C., Pavord, I.D., Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: A secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 3 (2015), 435–442.
50. Siddiqui, S.H., Guasconi, A., Vestbo, J., Jones, P., Agusti, A., Paggiaro, P., et al. Blood eosinophils: A biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 192 (2015), 523–525.
51. Pavord, I.D., Lettis, S., Anzueto, A., Barnes, N., Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: A patient-level meta-analysis. Lancet Respir Med 4 (2016), 731–741.
52. Nieto, A., Mazon, A., Pamies, R., Linana, J.J., Lanuza, A., Jiménez, F.O., et al. Adverse effects of inhaled corticosteroids in funded and nonfunded studies. Arch Intern Med 167 (2007), 2047–2053.
53. Kew, K.M., Seniukovich, A., Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev., 3, 2014 CD010115.
54. Finney, L., Berry, M., Singanayagam, A., Elkin, S.L., Johnston, S.L., Mallia, P., Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. Lancet Respir Med 2 (2014), 919–932.
55. Aaron, S.D., Vandemheen, K.L., Fergusson, D., Maltais, F., Bourbeau, J., Goldstein, R., et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: A randomized trial. Ann Intern Med 146 (2007), 545–555.
56. Karner, C., Cates, C.J., The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev., 9, 2011 CD009039.
57. Frith, P.A., Thompson, P.J., Ratnavadivel, R., Chang, C.L., Bremner, P., Day, P., et al., Glisten Study Group. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: The GLISTEN study, a randomised controlled trial. Thorax 70 (2015), 519–527.
58. Singh, D., Papi, A., Corradi, M., Pavlišová, I., Montagna, I., Francisco, C., et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): A double-blind, parallel group, randomised controlled trial. Lancet 388 (2016), 963–973.
59. Siler, T.M., Kerwin, E., Singletary, K., Brooks, J., Church, A., Efficacy and safety of umeclidinium added to fluticasone propionate/salmeterol in patients with COPD: Results of two randomized, double-blind studies. COPD 13 (2016), 1–10.
60. Zheng, J.P., Kang, J., Huang, S.G., Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): A randomized placebo-controlled study. Lancet 371 (2008), 2013–2018.
61. Decramer, M., Rutten-van, M.M., Dekhuijzen, P.N., Troosters, T., Van Herwaarden, C., Pellegrion, R., et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (bronchitis randomized on NAC cost-utility study, BRONCUS): A randomized placebo-controlled trial. Lancet 365 (2005), 1552–1560.
62. Tse, H.N., Raiteri, L., Wong, K.Y., Ng, L.Y., Yee, K.S., Tseng, C.Z., Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD. Chest 146 (2014), 611–623.
63. Zheng, J.P., Wen, F.Q., Bai, C.X., Wan, H.Y., Kang, J., Chen, P., et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): A randomised, double-blind placebo-controlled trial. Lancet Respir Med 2 (2014), 187–194.
64. Santos, S., Marin, A., Serra-Batlles, J., de la Rosa, D., Solanes, I., Pomares, X., et al. Treatment of patients with COPD and recurrent exacerbations: the role of infection and inflammation. Int J Chron Obst Pulm Dis 11 (2016), 515–525.
65. Fabbri, L.M., Calverley, P.M.A., Izquierdo-Alonso, J.L., Bundschuh, D.S., Brose, M., Martinez, F.J., et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: Two randomised clinical trials. Lancet 374 (2009), 695–703.
66. Bateman, E.D., Rabe, K.F., Calverley, P.M.A., Goehring, U.M., Brose, M., Bredenbroker, D., et al. Roflumilast with long-acting b2-agonists for COPD: Influence of exacerbation history. Eur Respir J 38 (2011), 553–560.
67. Martinez, F.J., Calverley, P.M., Goehring, U.M., Brose, M., Fabbri, L.M., Rabe, K.F., Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): A multicentre randomised controlled trial. Lancet 385 (2015), 857–866.
68. Martinez, F.J., Rabe, K.F., Sethi, S., Pizzichini, E., McIvor, A., Anzueto, A., et al. Effect of roflumilast and inhaled corticosteroid/long-acting β2-agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND). A randomized clinical trial. Am J Respir Crit Care Med 194 (2016), 559–567.
69. Uzun, S., Djamin, R.S., Kluytmans, J.A., Mulder, P.G., van't Veer, N.E., Ermens, A.A., et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): A randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2 (2014), 361–368.
70. Miravitlles, M., Anzueto, A., Antibiotic prophylaxis in COPD: Why, when, and for whom?. Pulm Pharmacol Ther 32 (2015), 119–123.
71. Ni, W., Shao, X., Cai, X., Wei, C., Cui, J., Wang, R., et al. Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: A meta-analysis. PLoS One, 10, 2015, e0121257.
72. Seemungal, T.A.R., Wilkinson, T.M.A., Hurst, J.R., Perera, W.R., Sapsford, R.J., Wedzicha, J.A., Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 178 (2008), 1139–1147.
73. Pomares, X., Montón, C., Espasa, M., Casabon, J., Monsó, E., Gallego, M., Long-term a1ithromycin therapy in patients with severe COPD and repeated exacerbations. Int J Chron Obst Respir Dis 6 (2011), 449–456.
74. Albert, R.K., Connett, J., Biley, W.C., Casaburi, R., Cooper, J.A.D., Criner, G.J., et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365 (2011), 689–698.
75. Miravitlles, M., Marín, A., Monsó, E., Vilà, S., de la Roza, C., Hervás, R., et al. Efficacy of moxifloxacin in the treatment of bronchial colonization in COPD. Eur Respir J 34 (2009), 1066–1071.
76. Sethi, S., Jones, P.W., Theron, M.S., Miravitlles, M., Rubinstein, E., Wedzicha, J.A., et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: A randomized controlled trial. Respir Res, 11, 2010, 10.
77. Sethi, S., Murphy, T.F., Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 359 (2008), 2355–2365.
78. Martínez-García, M.A., de la Rosa Carrillo, D., Soler-Cataluña, J.J., Donat-Sanz, Y., Serra, P.C., Lerma, M.A., et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 187 (2013), 823–831.
79. Vendrell, M., de Gracia, J., Olveira, C., Martínez, M.A., Girón, R., Máiz, L., et al. Diagnóstico y tratamiento de las bronquiectasias. Arch Bronconeumol 44 (2008), 629–640.
80. Cranston, J.M., Crockett, A.J., Moss, J.R., Alpers, J.H., Domiciliary oxygen for COPD. Cochrane Database Syst Rev, 2005, CD001744.
81. Kim, V., Benditt, J.O., Wise, R.A., Sharafkhaneh, A., Oxygen therapy in chronic obstructive pulmonary disease. Proc Am Thorac Soc 5 (2008), 513–518.
82. Long-Term Oxygen Treatment Trial Research Group. A Randomized trial of long-term oxygen for COPD with moderate desaturation. N Engl J Med 375 (2016), 1617–1627.
83. Ortega Ruiz, F., Díaz Lobato, S., Galdiz Iturri, J.B., García Rio, F., Güell Rous, R., Morante Velez, F., et al. SEPAR. Continuous home oxygen therapy. Arch Bronconeumol 50 (2014), 185–200.
84. Bradley, J.M., Lasserson, T., Elborn, S., Macmahon, J., O'Neill, B., A systematic review of randomized controlled trials examining the short-term benefit of ambulatory oxygen in COPD. Chest 131 (2007), 278–285.
85. American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with alpha-1-antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:820-99.
86. Casas, F., Blanco, I., Martínez, M.T., Bustamante, A., Miravitlles, M., Cadenas, S., et al. Indications for active case searches and intravenous alpha-1 antitrypsin treatment for patients with alpha-1 antitrypsin deficiency chronic obstructive pulmonary disease: An update. Arch Bronconeumol 51 (2015), 185–192.
87. Chapman, K.R., Burdon, J.G.W., Piitulainen, E., Sandhaus, R.A., Seersholm, N., Stocks, J.M., et al., RAPID Trial Study Group. Intravenous augmentation treatment and lung density in severe alpha-1 antitrypsin deficiency (RAPID): A randomised, double-blind, placebo-controlled trial. Lancet 386 (2015), 360–368.
88. Stockley, R.A., Miravitlles, M., Vogelmeier, C., Augmentation therapy for alpha-1 antitrypsin deficiency: Towards a personalised approach. Orphanet J Rare Dis, 8, 2013, 149.
89. Lara, B., Blanco, I., Martínez, M.T., Rodríguez, E., Bustamante, A., Casas, F., et al. Spanish registry of patients with alpha-1 antitrypsin deficiency: Database evaluation and population analysis. Arch Bronconeumol 53 (2017), 13–18.
90. Adams, S.G., Anzueto, A., Briggs, D.D. Jr., Leimer, I., Kesten, S., Evaluation of withdrawal of maintenance tiotropium in COPD. Respir Med 103 (2009), 1415–1420.
91. Alcázar Navarrete, B., Casanova, C., Miravitlles, M., de Lucas, P., Riesco, J.A., Rodríguez González-Moro, J.M., Correct use of inhaled corticosteroids in chronic obstructive pulmonary disease: A consensus document. Arch Bronconeumol 51 (2015), 193–198.
92. Kunz, L.I., Ten Hacken, N.H., Lapperre, T.S., Timens, W., Kerstjens, H.A., van Schadewijk, A., et al., GLUCOLD Study Group. Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids. Eur Respir J, 2017 Jan 3;49(1). pii: 1600839. doi:10.1183/13993003.00839-2016.
93. Van der Valk, P., Monninkhof, E., van del Palen, J., Zielhuis, G., van Herwaarden, C., Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. The COPE study. Am J Respir Crit Care Med 166 (2002), 1358–1363.
94. Rossi, A., Guerriero, M., Corrado, A., OPTIMO/AIPO Study Group. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: A real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res, 15, 2014, 77.
95. Magnussen, H., Disse, B., Rodriguez-Roisin, R., Kirsten, A., Watz, H., Tetzlaff, K., et al., WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 371 (2014), 1285–1294.
96. Watz, H., Tetzlaff, K., Wouters, E.F., Kirsten, A., Magnussen, H., Rodriguez-Roisin, R., et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 4 (2016), 390–398.
97. Rossi, A., van der Molen, T., del Olmo, R., Papi, A., Wehbe, L., Quinn, M., et al. INSTEAD: A randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J 44 (2014), 1548–1556.
98. Nighat, J., Nadeem, N.J., Taylor, S., Eldridge, S.M., Withdrawal of inhaled corticosteroids in individuals with COPD - a systematic review and comment on trial methodology. Respir Res, 12, 2011, 107.